Finanzen von Regencell Bioscience Holdings Ltd (RGC)RGCRegencell Bioscience Holdings Ltd

Evaluating the bottom line, Regencell Bioscience Holdings Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -177.66%, provide a clear picture of how effectively RGC converts its operational activities into shareholder value.

In the context of the broader market, RGC competes directly with industry leaders such as ATAI and SLS. With a market capitalization of $2.73B, it holds a leading position in the sector. When comparing efficiency, RGC's gross margin of N/A stands against ATAI's 100.00% and SLS's N/A. Such benchmarking helps identify whether Regencell Bioscience Holdings Ltd is trading at a premium or discount relative to its financial performance.

The company has a forward P/E ratio of 0, indicating no expected earnings growth, and a price-to-sales ratio of 0, which suggests it is not generating revenue effectively. The gross margin is not provided, but the negative cash flow metrics (FCF yield of -0.0989) indicate financial instability.